CYTH News and Press, Cyclo Therapeutics Inc. From 06/05/23

2023-06-05 09:24:20 ET Clinical stage biotechnology company, Cyclo Therapeutics ( NASDAQ: CYTH ) enters into an agreement with Rafael ( NYSE: RFL ) to purchase 4M shares and warrants for an aggregate purchase price of $5M. The warrants will have an exercise price o...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...

Company on track to complete enrollment in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) by year end 2023 Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” ...

2023-05-04 08:00:00 ET Summary Many treatments for Alzheimer's disease limit the formation of peroxynitrite, which can for a while slow down the progression of the disease. A few treatments for Alzheimer's disease can also scavenge peroxynitrite and reverse some of the damage that...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...

2023-03-20 08:58:31 ET Cyclo Therapeutics press release ( NASDAQ: CYTH ): Q4 GAAP EPS of -$0.59. Revenue of $186.8M. For further details see: Cyclo Therapeutics GAAP EPS of -$0.59, revenue of $186.8M

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) projected 40% enrolled by the end of March; Company on track to complete enrollment by year end 2023 Phase 2b study of Trappsol ® Cyclo...

- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...

Continued progress in ongoing pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) with 35% of expected enrollment completed, on track to complete enrollment by year end 2023 Patient enrollment and dos...